18:36 , Nov 30, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: November 2017

New Therapeutic Targets and Biomarkers: November 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during November 2017. Therapeutic targets are defined as any protein, gene or other molecule...
17:05 , Nov 8, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Inflammatory bowel disease (IBD) Cell culture and mouse studies suggest stimulating T cells with a nine-mer G6PC2 peptide or its Bacteroides integrase-derived homolog could help treat IBD. In a mouse model of chemical-induced IBD, adoptive...
08:00 , Mar 10, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Major histocompatibility complex class II (MHCII); glucose-6-phosphatase catalytic 2 (G6PC2; IGRP); proteolipid protein 1 (PLP1); myelin oligodend

Autoimmune disease INDICATION: Diabetes; rheumatoid arthritis (RA); multiple sclerosis (MS) Mouse studies suggest nanoparticles coated with MHCII molecules bound to disease-relevant peptides could help treat Type I diabetes, RA and MS. In a mouse model of Type...
07:00 , Oct 9, 2014 |  BC Innovations  |  Targets & Mechanisms

BetaLogics' in vitro beta cells

BetaLogics Venture and The University of British Columbia have developed an in vitro protocol to generate mature insulin-producing pancreatic b-like cells from human pluripotent stem cells.1 The findings mark a major milestone for the development...
07:00 , May 15, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease ...